Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.51 |
| ▸ | SLC9A2 | Q9UBY0 | 2/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399279 | 0.82 | KDM4E (0.56) | P2RX7KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL1752087 | 0.79 | P2RX7 (0.53) | P2RX7KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL6311452 | 0.74 | HDAC1 (0.51) | P2RX7KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL6263444 | 0.73 | KDM4E (0.72) | SLC9A1SLC9A2KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL6312375 | 0.73 | CYP2C9 (0.45) | SLC9A1SLC9A2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL13543694 | 0.72 | P2RX7 (0.46) | P2RX7KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL32674134 | 0.72 | MAPT (0.59) | P2RX7KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL6464483 | 0.72 | HDAC1 (0.55) | P2RX7KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL14736048 | 0.72 | P2RX7 (0.63) | P2RX7KDM4EALDH1A1HPGDMEN1 | |
| Hydrochloric Acid SCHEMBL6313771 | 0.72 | KDM4E (0.70) | SLC9A1SLC9A2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
| CN-1289326-A | N-[(substituted five-membered di-or thiaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER PROD INC (US) | 2001-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | SLC9A1 5/4885SLC9A2 12/4885P2RX7 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.